197 related articles for article (PubMed ID: 34094073)
1. Ligand-centred redox activation of inert organoiridium anticancer catalysts.
Zhang WY; Banerjee S; Hughes GM; Bridgewater HE; Song JI; Breeze BG; Clarkson GJ; Coverdale JPC; Sanchez-Cano C; Ponte F; Sicilia E; Sadler PJ
Chem Sci; 2020 May; 11(21):5466-5480. PubMed ID: 34094073
[TBL] [Abstract][Full Text] [Related]
2. Organoiridium complexes: anticancer agents and catalysts.
Liu Z; Sadler PJ
Acc Chem Res; 2014 Apr; 47(4):1174-85. PubMed ID: 24555658
[TBL] [Abstract][Full Text] [Related]
3. Catalytic organometallic anticancer complexes.
Dougan SJ; Habtemariam A; McHale SE; Parsons S; Sadler PJ
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11628-33. PubMed ID: 18687892
[TBL] [Abstract][Full Text] [Related]
4. DFT Investigation of the Mechanism of Action of Organoiridium(III) Complexes As Anticancer Agents.
Ritacco I; Russo N; Sicilia E
Inorg Chem; 2015 Nov; 54(22):10801-10. PubMed ID: 26492153
[TBL] [Abstract][Full Text] [Related]
5. The potent oxidant anticancer activity of organoiridium catalysts.
Liu Z; Romero-Canelón I; Qamar B; Hearn JM; Habtemariam A; Barry NP; Pizarro AM; Clarkson GJ; Sadler PJ
Angew Chem Int Ed Engl; 2014 Apr; 53(15):3941-6. PubMed ID: 24616129
[TBL] [Abstract][Full Text] [Related]
6. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
7. Glutathione activation of an organometallic half-sandwich anticancer drug candidate by ligand attack.
Zhang X; Ponte F; Borfecchia E; Martini A; Sanchez-Cano C; Sicilia E; Sadler PJ
Chem Commun (Camb); 2019 Dec; 55(97):14602-14605. PubMed ID: 31742266
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.
Yang Y; Guo L; Ge X; Shi S; Gong Y; Xu Z; Zheng X; Liu Z
J Inorg Biochem; 2019 Feb; 191():1-7. PubMed ID: 30445339
[TBL] [Abstract][Full Text] [Related]
9. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
[TBL] [Abstract][Full Text] [Related]
10. Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.
Hearn JM; Hughes GM; Romero-Canelón I; Munro AF; Rubio-Ruiz B; Liu Z; Carragher NO; Sadler PJ
Metallomics; 2018 Jan; 10(1):93-107. PubMed ID: 29131211
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes.
Gupta G; Garci A; Murray BS; Dyson PJ; Fabre G; Trouillas P; Giannini F; Furrer J; Süss-Fink G; Therrien B
Dalton Trans; 2013 Nov; 42(43):15457-63. PubMed ID: 24022745
[TBL] [Abstract][Full Text] [Related]
12. Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts.
Geldmacher Y; Splith K; Kitanovic I; Alborzinia H; Can S; Rubbiani R; Nazif MA; Wefelmeier P; Prokop A; Ott I; Wölfl S; Neundorf I; Sheldrick WS
J Biol Inorg Chem; 2012 Apr; 17(4):631-46. PubMed ID: 22358334
[TBL] [Abstract][Full Text] [Related]
13. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
14. Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.
Li J; Guo L; Tian Z; Tian M; Zhang S; Xu K; Qian Y; Liu Z
Dalton Trans; 2017 Nov; 46(44):15520-15534. PubMed ID: 29090698
[TBL] [Abstract][Full Text] [Related]
15. Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp
Guo L; Li P; Li J; Gong Y; Li X; Liu Y; Yu K; Liu Z
Inorg Chem; 2023 Sep; 62(37):15118-15137. PubMed ID: 37671819
[TBL] [Abstract][Full Text] [Related]
16. Anticancer application of ferrocene appended configuration-regulated half-sandwich iridium(III) pyridine complexes.
Wang Z; Lv Z; Liu X; Wu Y; Chang J; Dong R; Li C; Yuan XA; Liu Z
J Inorg Biochem; 2022 Dec; 237():112010. PubMed ID: 36152469
[TBL] [Abstract][Full Text] [Related]
17. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs.
Jansen BA; Brouwer J; Reedijk J
J Inorg Biochem; 2002 Apr; 89(3-4):197-202. PubMed ID: 12062123
[TBL] [Abstract][Full Text] [Related]
18. A New Paradigm in Pincer Iridium Chemistry: PCN Complexes for (De)Hydrogenation Catalysis and Beyond.
Wang Y; Huang Z; Liu G; Huang Z
Acc Chem Res; 2022 Aug; 55(15):2148-2161. PubMed ID: 35852837
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships for osmium(II) arene phenylazopyridine anticancer complexes functionalised with alkoxy and glycolic substituents.
Needham RJ; Bridgewater HE; Romero-Canelón I; Habtemariam A; Clarkson GJ; Sadler PJ
J Inorg Biochem; 2020 Sep; 210():111154. PubMed ID: 32771772
[TBL] [Abstract][Full Text] [Related]
20. Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.
Zheng Y; He L; Zhang DY; Tan CP; Ji LN; Mao ZW
Dalton Trans; 2017 Aug; 46(34):11395-11407. PubMed ID: 28813052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
